Clinical trial · Interventional
Amifostine for Head and Neck Irradiation in Lymphoma
A Randomized Phase II Trial of Amifostine for Head and Neck Irradiation in Lymphoma
NCT00136474CI-TRIAL-00002755completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is determine the effects (good and bad) amifostine has on radiation-induced side effects of lymphoma treatment.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin's Disease | Hodgkin Lymphoma | ALIAS | 0.90 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Amifostine | Drug | — | UNRESOLVED |
| Radiation Therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Group 1
- description
- Amifostine plus radiation therapy
- interventionNames
- Drug: Amifostine
- Radiation: Radiation Therapy
- type
- ACTIVE_COMPARATOR
- label
- Group 2
- description
- Radiation therapy alone
- interventionNames
- Radiation: Radiation Therapy
Primary outcomes (1)
- measure
- To evaluate the effectiveness of amifostine in reducing acute and chronic radiation-induced side effects
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must be 35 years or older * Histologically confirmed Hodgkin's disease or non-Hodgkin's lymphoma receiving radiation therapy to the head and neck area. * Involvement of one or more of the following sites: cervical node, supraclavicular node, pre-auricular node, submental node, any salivary glands, any parts of the oral cavity, or any parts of the oropharynx. Exclusion Criteria: * Prior history of head and neck malignancies * Prior radiation therapy to the head and neck region * Patients with stage I Hodgkin's disease receiving radiation therapy alone * Pregnant or lactating women * Myocardial infarction within the 6 months of enrollment * Clinically evident pulmonary insufficiency, except for patients with exertional dyspnea related to chest tumor itself.
References
Publications (0)
Data not yet available
No reference posted for this study.